Compare
Inogen Inc vs Establishment Labs Holdings Inc. vs Cadre Holdings, Inc. vs Sanara MedTech Inc.
| Latest fiscal year | Inogen Inc INGN | Establishment Labs Holdings Inc. ESTA | Cadre Holdings, Inc. CDRE | Sanara MedTech Inc. SMTI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $348.67M | $211.08M | $610.31M | $103.12M |
| Revenue growth (YoY) | +3.9% | +27.1% | +7.5% | +19.0% |
| Gross margin | 44.2% | 69.3% | 42.5% | 92.7% |
| Operating margin | -8.7% | -18.5% | 11.0% | 7.1% |
| Net margin | -6.5% | -24.2% | 7.2% | -36.4% |
| Net income | -$22.75M | -$51.06M | $44.14M | -$37.56M |
| EPS (Diluted) | -$0.86 | -$1.72 | $1.02 | -$4.36 |
| Operating cash flow | -$11.22M | -$50.89M | $63.70M | $6.79M |
| Free cash flow | -$13.74M | -$56.94M | $56.85M | $2.16M |
| Cash & equivalents | $103.73M | $75.57M | $122.90M | $16.58M |
| Total assets | $298.62M | $357.17M | $770.03M | $72.94M |
| Total liabilities | $106.39M | $333.62M | $452.23M | $67.01M |
| Shareholders' equity | $192.23M | $23.55M | $317.80M | $5.94M |
| Return on year-end equity | -11.8% | -216.9% | 13.9% | -632.5% |
| Shares outstanding | 27.23M | 29.30M | 42.16M | 8.95M |
Revenue, most recent five fiscal years
| Fiscal year | Inogen Inc | Establishment Labs Holdings Inc. | Cadre Holdings, Inc. | Sanara MedTech Inc. |
|---|---|---|---|---|
| Latest | $348.67M Ended 2025-12-31 | $211.08M Ended 2025-12-31 | $610.31M Ended 2025-12-31 | $103.12M Ended 2025-12-31 |
| 1 year earlier | $335.70M Ended 2024-12-31 | $166.03M Ended 2024-12-31 | $567.56M Ended 2024-12-31 | $86.67M Ended 2024-12-31 |
| 2 years earlier | $315.66M Ended 2023-12-31 | $165.15M Ended 2023-12-31 | $482.53M Ended 2023-12-31 | $64.99M Ended 2023-12-31 |
| 3 years earlier | $377.24M Ended 2022-12-31 | $161.70M Ended 2022-12-31 | $457.84M Ended 2022-12-31 | $45.84M Ended 2022-12-31 |
| 4 years earlier | $358.00M Ended 2021-12-31 | $126.68M Ended 2021-12-31 | $427.29M Ended 2021-12-31 | $24.14M Ended 2021-12-31 |